{"id":5114,"date":"2025-05-19T11:23:31","date_gmt":"2025-05-19T10:23:31","guid":{"rendered":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/?p=5114"},"modified":"2025-05-20T16:26:36","modified_gmt":"2025-05-20T15:26:36","slug":"revolutionising-research-with-innovative-clinical-trials","status":"publish","type":"post","link":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/","title":{"rendered":"Revolutionising research with innovative clinical trials"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"1384\" height=\"925\" class=\"aligncenter size-full wp-image-5115\" src=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/otavio-berwanger.jpg\" alt=\"Prof Otavio Berwanger\" \/><\/p>\n<p><strong>On Clinical Trials Day, <a href=\"https:\/\/www.imperial.ac.uk\/news\/262273\/professor-berwanger-appointed-chair-international-clinical\/\">Prof Otavio Berwanger<\/a>, Executive Director of <a href=\"https:\/\/www.georgeinstitute.org\/\">The George Institute for Global Health<\/a> and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research.<\/strong><\/p>\n<hr \/>\n<p>Large-scale and high-quality randomised controlled trials (RCTs) are considered the gold standard in clinical research. Study participants are randomly allocated to intervention or control groups and their outcomes are compared, minimising bias and providing reliable evidence about the efficacy and safety of treatments. Clinical trials have been vital to some of the biggest advances in modern medicine, but they are not without their drawbacks.<\/p>\n<p>Conducting RCTs is an expensive, time-consuming, and complex process. They take several years to complete and cost millions of pounds;. Participants are also required to travel to central trial sites for assessments, making patient recruitment and participation difficult.<\/p>\n<p>In response to these challenges, we have formed the <a href=\"https:\/\/www.georgeinstitute.org\/our-research\/clinical-and-community-trials\/innovative-clinical-trials\">Innovative Clinical Trials Hub.<\/a> The hub aims to support projects across <a href=\"https:\/\/www.georgeinstitute.org\/\">The George Institute<\/a>, <a href=\"https:\/\/www.imperial.ac.uk\/\">Imperial<\/a> and those led by external organisations, to design, deliver and analyse innovative, efficient, and impactful, large-scale, patient-centric trials. In this sense, we are very proud of our excellent partnership with the Imperial Clinical Trials Unit (ICTU) and we will definitely work together in delivering high-quality, innovative trials. Similarly, we see great opportunities for developing efficient trial models in other regions, including Australia (where we have a strong partnership with the University of New South Wales -UNSW) and India. \u00a0I am also very excited to collaborate with the UKCRC Clinical Trial Units network in my capacity as the new Chair of the International Registration Review Committee.<\/p>\n<p><!--more--><\/p>\n<p>Key to this is decentralised clinical trials (DCTs), which use digital technology to shift routine trial activities away from distant study sites. Tools such as mobile apps, interactive e-consent platforms, wearables, and video conferencing can enable at-home data collection and consultations with clinical staff.<\/p>\n<p>This added convenience not only has the potential to improve participant retention but can also strengthen inclusivity in clinical trials. The logistical burden of traditional trials has led to exclusion of key demographics from clinical research. <a href=\"https:\/\/research.regionh.dk\/en\/publications\/how-to-make-cardiology-clinical-trials-more-inclusive\">Historically, 70% of clinical trial participants have been white males, and trial diversity remains a major issue within my own field of cardiology \u2013 contributing to poorer health outcomes in women and ethnic minority groups.<\/a><\/p>\n<p>DCTs can help remove barriers to enrolment, by reducing conflicts with work and caregiving responsibilities, minimising transportation challenges, and lowering time and financial burdens on participants.<\/p>\n<p>By utilising smart monitoring devices and wearable technology (like smartwatches, for example), these innovative trial designs can collect data more efficiently and comprehensively than traditional site-based visits allow.<\/p>\n<p>Additionally, the use of routinely collected data, that is primarily documented in everyday practice rather than for research, offers further potential to improve upon standard randomised controlled trials. In this sense, routinely collected data can speed up screening and recruitment, enable efficient endpoint ascertainment and decrease the burden on research teams and trial participants.<\/p>\n<p>Finally, it is important to avoid unnecessary and unjustified complexity in clinical trials. In most cases, large, simple trial designs\u2014focused on a relevant clinical question, with data collection limited to the most important variables to answer this question and conducted in broad patient populations\u2014and pragmatic trials, which assess the effectiveness of interventions under real-world conditions, are best suited to provide reliable answers to clinicians\u2019 questions. When embedded within registries and routine clinical practice, these trials can also be delivered more efficiently, both in terms of time and cost.<\/p>\n<p>Lockdown and social distancing during the COVID-19 pandemic has accelerated the implementation of innovative clinical trials, but we still have a long way to go. To ensure the success of such clinical trials moving forward, issues related to quality, data protection, digital literacy, and regulatory preparedness must be addressed.<\/p>\n<p>The future of innovative clinical trials is promising, offering several benefits to patients, researchers and industry. Through innovative methods, we can improve the patient experience, generate more comprehensive data, reduce costs, and ultimately, ensure better health outcomes for all patients.<\/p>\n<p><strong>Catch the replay of Prof Otavio&#8217;s Imperial Inaugural:<\/strong><\/p>\n<p><span class=\"yt-core-attributed-string yt-core-attributed-string--white-space-pre-wrap\" dir=\"auto\"><span class=\"yt-core-attributed-string--link-inherit-color\" dir=\"auto\">Professor Otavio Berwanger, Executive Director for The George Institute for Global Health, and Chair in Clinical Trials, discusses innovative clinical trial designs, patient-centred approaches, and digital technologies to transform healthcare research<\/span><\/span>. Click the image below to watch the replay.\u00a0<a href=\"https:\/\/www.youtube.com\/watch?v=LU7R1ixe_oc\"><br \/>\n<img loading=\"lazy\" decoding=\"async\" width=\"1918\" height=\"842\" class=\"aligncenter size-full wp-image-5123\" src=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-20-at-16.19.45.png\" alt=\"\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On Clinical Trials Day, Prof Otavio Berwanger, Executive Director of The George Institute for Global Health and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research. Large-scale and high-quality randomised controlled trials (RCTs) are considered the gold standard in [&hellip;]<\/p>\n","protected":false},"author":1909,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[226],"tags":[16293],"class_list":["post-5114","post","type-post","status-publish","format-standard","hentry","category-school-of-public-health","tag-clinical-trials"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revolutionising research with innovative clinical trials - Imperial Medicine Blog<\/title>\n<meta name=\"description\" content=\"Prof Otavio Berwanger, Executive Director of The George Institute for Global Health and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolutionising research with innovative clinical trials - Imperial Medicine Blog\" \/>\n<meta property=\"og:description\" content=\"Prof Otavio Berwanger, Executive Director of The George Institute for Global Health and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Imperial Medicine Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-19T10:23:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-20T15:26:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/otavio-berwanger.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1384\" \/>\n\t<meta property=\"og:image:height\" content=\"925\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Otavio Berwanger\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Otavio Berwanger\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/\"},\"author\":{\"name\":\"Otavio Berwanger\",\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/#\\\/schema\\\/person\\\/c790ca8e1f2ab70e8273ffac86cde784\"},\"headline\":\"Revolutionising research with innovative clinical trials\",\"datePublished\":\"2025-05-19T10:23:31+00:00\",\"dateModified\":\"2025-05-20T15:26:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/\"},\"wordCount\":727,\"image\":{\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/files\\\/2025\\\/05\\\/otavio-berwanger.jpg\",\"keywords\":[\"Clinical trials\"],\"articleSection\":[\"School of Public Health\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/\",\"name\":\"Revolutionising research with innovative clinical trials - Imperial Medicine Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/files\\\/2025\\\/05\\\/otavio-berwanger.jpg\",\"datePublished\":\"2025-05-19T10:23:31+00:00\",\"dateModified\":\"2025-05-20T15:26:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/#\\\/schema\\\/person\\\/c790ca8e1f2ab70e8273ffac86cde784\"},\"description\":\"Prof Otavio Berwanger, Executive Director of The George Institute for Global Health and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research.\",\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/2025\\\/05\\\/19\\\/revolutionising-research-with-innovative-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/files\\\/2025\\\/05\\\/otavio-berwanger.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/files\\\/2025\\\/05\\\/otavio-berwanger.jpg\",\"width\":1384,\"height\":925,\"caption\":\"Prof Otavio Berwanger\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/#website\",\"url\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/\",\"name\":\"Imperial Medicine Blog\",\"description\":\"Stories from Imperial&#039;s Faculty of Medicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/#\\\/schema\\\/person\\\/c790ca8e1f2ab70e8273ffac86cde784\",\"name\":\"Otavio Berwanger\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cd2d558374978a87ca8f1f7f3741b3c4a74ccb49b92ed3894fbe74c1804b8a99?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cd2d558374978a87ca8f1f7f3741b3c4a74ccb49b92ed3894fbe74c1804b8a99?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cd2d558374978a87ca8f1f7f3741b3c4a74ccb49b92ed3894fbe74c1804b8a99?s=96&d=mm&r=g\",\"caption\":\"Otavio Berwanger\"},\"url\":\"https:\\\/\\\/blogs.imperial.ac.uk\\\/imperial-medicine\\\/author\\\/oberwang\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolutionising research with innovative clinical trials - Imperial Medicine Blog","description":"Prof Otavio Berwanger, Executive Director of The George Institute for Global Health and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/","og_locale":"en_GB","og_type":"article","og_title":"Revolutionising research with innovative clinical trials - Imperial Medicine Blog","og_description":"Prof Otavio Berwanger, Executive Director of The George Institute for Global Health and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research.","og_url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/","og_site_name":"Imperial Medicine Blog","article_published_time":"2025-05-19T10:23:31+00:00","article_modified_time":"2025-05-20T15:26:36+00:00","og_image":[{"width":1384,"height":925,"url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/otavio-berwanger.jpg","type":"image\/jpeg"}],"author":"Otavio Berwanger","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Otavio Berwanger","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/"},"author":{"name":"Otavio Berwanger","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/c790ca8e1f2ab70e8273ffac86cde784"},"headline":"Revolutionising research with innovative clinical trials","datePublished":"2025-05-19T10:23:31+00:00","dateModified":"2025-05-20T15:26:36+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/"},"wordCount":727,"image":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/otavio-berwanger.jpg","keywords":["Clinical trials"],"articleSection":["School of Public Health"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/","url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/","name":"Revolutionising research with innovative clinical trials - Imperial Medicine Blog","isPartOf":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/otavio-berwanger.jpg","datePublished":"2025-05-19T10:23:31+00:00","dateModified":"2025-05-20T15:26:36+00:00","author":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/c790ca8e1f2ab70e8273ffac86cde784"},"description":"Prof Otavio Berwanger, Executive Director of The George Institute for Global Health and Chair in Clinical Trials at Imperial College London, shares how rethinking the design and delivery of clinical trials can benefit all involved in medical research.","inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/19\/revolutionising-research-with-innovative-clinical-trials\/#primaryimage","url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/otavio-berwanger.jpg","contentUrl":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/otavio-berwanger.jpg","width":1384,"height":925,"caption":"Prof Otavio Berwanger"},{"@type":"WebSite","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#website","url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/","name":"Imperial Medicine Blog","description":"Stories from Imperial&#039;s Faculty of Medicine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/c790ca8e1f2ab70e8273ffac86cde784","name":"Otavio Berwanger","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/cd2d558374978a87ca8f1f7f3741b3c4a74ccb49b92ed3894fbe74c1804b8a99?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/cd2d558374978a87ca8f1f7f3741b3c4a74ccb49b92ed3894fbe74c1804b8a99?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cd2d558374978a87ca8f1f7f3741b3c4a74ccb49b92ed3894fbe74c1804b8a99?s=96&d=mm&r=g","caption":"Otavio Berwanger"},"url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/author\/oberwang\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pg9uH0-1ku","jetpack_likes_enabled":false,"_links":{"self":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts\/5114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/users\/1909"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/comments?post=5114"}],"version-history":[{"count":6,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts\/5114\/revisions"}],"predecessor-version":[{"id":5126,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts\/5114\/revisions\/5126"}],"wp:attachment":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/media?parent=5114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/categories?post=5114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/tags?post=5114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}